Bxcl701, First-In-Class Oral Activator Of Systemic Innate Immunity Pathway, Combined With Pembrolizumab (Keytruda) In Men With Metastatic Castration-Resistant Prostate Cancer (Mcrpc).

Rahul Raj Aggarwal,Dan Costin,Jingsong Zhang,Lawrence Ivan Karsh,Diane I. Healey,Mark David Linch,Sreenivas Adurthi,Daniel Peter Petrylak,Vince O'Neill,Paul Monk

JOURNAL OF CLINICAL ONCOLOGY（2021）

引用 2|浏览2

暂无评分

摘要

124Background: BXCL701 (talabostat), oral small molecule inhibitor of dipeptidyl peptidases (DPP), primarily DPP8 and DPP9, triggers inflammasome mediated pyroptosis in macrophages, leading to indu...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要